搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
12 天
Sage Therapeutics目标价因研究失望而下调至9美元
周二,Oppenheimer调整了对Sage Therapeutics (NASDAQ:SAGE)的展望,将目标价从之前的10美元下调至9美元,同时维持对该股的"表现"评级。这一调整是在Sage宣布其药物dalzanemdor未能在评估阿尔茨海默病相关轻度认知障碍(AD-MCI)患者治疗的2期LIGHTWAVE研究中达到主要目标之后做出的。 LIGHTWAVE研究的结果被视为一个挫折,尽管在该药物 ...
FierceBiotech
12 天
Sage scraps Alzheimer's program as dalzanemdor goes 0 for 2, leaving hopes resting on ...
Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...
alzheimersnewstoday
3 天
Dalzanemdor halted for Alzheimer’s; fails to boost cognitive function
Sage plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s after it failed to boost cognitive function in a Phase 2 ...
14 天
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...
BioSpace
12 天
Sage Suffers Third Neuro Stumble in Six Months With Disappointing Mid-Stage Alzheimer’s ...
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...
3 天
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus ...
12 天
on MSN
Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment
The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.
12 天
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage ...
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues ...
12 天
Sage halts another drug trial, this time in Alzheimer’s disease
Sage Therapeutics said its Phase 2 trial of dalzanemdor in patients with mild cognitive impairment or mild dementia due to ...
10 天
Sage Therapeutics price target lowered to $8 from $9 at Wedbush
Wedbush lowered the firm’s price target on Sage Therapeutics to $8 from $9 and keeps a Neutral rating on the shares. The firm ...
13 天
Sage Therapeutics Phase 2 LIGHTWAVE Study In Alzheimer's Disease Fails; Stock Down In Pre ...
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...
12 天
on MSN
Sage Therapeutics stock drops after disappointing Alzheimer's trial results
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈